BUZZ-BTG hit by U.S. coding setback for varicose vein treatment

** BTG (LSE: BTG.L - news) shares down more than 5% as new varicose vein treatment Varithena fails to be assigned unique product code under U.S (Other OTC: UBGXF - news) . Medicare and Medicaid systems

** Varithena's slow uptake has disappointed the market and lack of a unique code may continue to cause delays and obstacles to reimbursement, investors fear, offsetting solid first-half results

** Deutsche Bank (Other OTC: DBAGF - news) says fact BTG no longer expects to receive a dedicated so-called "J code" for reimbursement of Varithena may be seen as a setback, but it notes the company still expects a pick-up in sales of the product in 2016/17

(RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)